Companies › AC Immune
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Neurology, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACI-7104.056 Adjuvanted alpha-synuclein peptide conjugate vaccine | SNCA | Phase 2 | Parkinson Disease | Jun 2028 |
| ACI-19764 NLRP3 inflammasome inhibitor | NLRP3 | Phase 1 | Healthy Participants | Dec 2026 |
| ACI-24.060 | – | Phase 1 | Amyloid Plaque | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07463196 | ACI-19764 | Phase 1 | Healthy Participants | Metabolic and endocrine | Dec 2026 |
| NCT06015841 | ACI-7104.056 | Phase 2 | Parkinson Disease | Neurology | Jun 2028 |
| NCT05462106 | ACI-24.060 | Phase 1 | Amyloid Plaque | Neurology | Apr 2029 |
Cash of 27m CHF on 2025-12-31; operating cash outflow about 69m CHF a year; runway about 5 months at that burn, to May 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Highlightll Pharmaceutical (USA) Olatec Therapeutics Teva Branded Pharmaceutical Products R&D Regeneron Pharmaceuticals Roche XingImaging
IGC Pharma Denali Therapeutics Cytopeutics Sdn. Bhd. Larimar Therapeutics NKGen Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.